About asthma
Asthma is a disease that affects the lungs and is characterized by wheezing, coughing, breathlessness, and chest tightness. It is a chronic ailment of the respiratory tract, which is caused by the obstruction of the flow of air and bronchospasms, where the muscles around the respiratory tract swell up. The disease is believed to be caused by genetic as well as environmental factors. The American Academy of Allergy Asthma and Immunology classifies asthma under four categories: exercise-induced asthma, allergic asthma, occupational asthma, and childhood asthma. The Asthma and Allergy Foundation of America classifies asthma into two categories: allergic asthma and non-allergic asthma. It is an incurable disease but can be controlled with the help of diagnosis at the right time, followed by regular therapy.
Technavio's analysts forecast the asthma drugs market in the US to grow at a CAGR of 4.64% over the period 2014-2019.
Covered in this report
This report covers the present scenario and the growth prospects of the asthma drugs market in the US for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sale of various classes of drugs used to treat asthma, which include:
• Bronchodilators
• Leukotriene antagonists
• Mast cell stabilizers
• Immunosuppressants
• Combination of LABAICS
Technavio's report, Asthma Drugs Market in the US 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• AstraZeneca
• F. Hoffmann-La Roche
• GlaxoSmithKline
• Merck
Other prominent vendors
• Abbott Laboratories
• Addex Therapeutics
• Alkermes
• AstraZeneca
• Aurobindo Pharma
• Avanir Pharmaceuticals
• Cerecor
• Chugai Pharmaceutical
• Dart NeuroScience
• Dr. Reddy's Laboratories
• Edgemont Pharmaceuticals
• E-Therapeutics
• Euthymics
• Evotec
• F. Hoffmann-La Roche
• Fabre Kramer
• Gedeon Richter
• H. Lundbeck
• Intra-Cellular Therapies
• Janssen Pharmaceuticals
• Lupin
• Luye Pharma
• MSI Methylation Sciences
• Naurex
• Neuralstem
• Novartis
• Opko Health
• Otsuka Pharmaceutical
• Pierre Fabre
• Shire
• SK Biopharmaceuticals
• Somerset Pharmaceuticals
• Sun Pharmaceutical
• Sunovion Pharmaceuticals
• Suven
• Takeda Pharmaceutical
• Teva Pharmaceutical
• Torrent Pharmaceuticals
• Valeant Pharmaceuticals
Market driver
• Rise in disease prevalence
• For a full, detailed list, view our report
Market challenge
• Unknown disease etiology
• For a full, detailed list, view our report
Market trend
• Popularity of combination therapies
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market overview
03.2 Product offerings
04. Product Profiles
04.1.1 Accolate
04.1.2 Pulmicort
04.1.3 Symbicort
04.1.4 Xolair
04.1.5 Advair
04.1.6 Anoro Ellipta
04.1.7 Arnuity Ellipta
04.1.8 Breo Ellipta
04.1.9 Flovent
04.1.10 Serevent
04.1.11 Ventolin
04.1.12 Asmanex
04.1.13 Foradil
04.1.14 Dulera
04.1.15 Singulair
05. Market Research Methodology
05.1 Market research process
05.2 Research methodology
06. Introduction
07. Disease Overview
07.1 Understanding the disease
07.2 Symptoms
07.3 Pathophysiology
07.3.1 Airway inflammation
07.3.2 Airway remodeling
07.4 Epidemiology
07.5 Diagnosis
07.6 Management
08. Pipeline Portfolio
09. Market Landscape
09.1 Market overview
09.2 Market size and forecast
09.3 Five forces analysis
10. Market Segmentation by Class of Drug
11. Bronchodilators
11.1 Bronchodilators market in US
11.1.1 Market overview
11.1.2 Market size and forecast
12. Combination of LABAICS
12.1 Combination of LABAICS market in US
12.1.1 Market overview
12.1.2 Market size and forecast
13. Immunosuppressants
13.1 Immunosuppressants market in US
13.1.1 Market overview
13.1.2 Market size and forecast
14. Leukotriene Antagonists
14.1 Leukotriene antagonists market in US
14.1.1 Market overview
14.1.2 Market size and forecast
15. Mast Cell Stabilizers
15.1 Mast cell stabilizers market in US
15.1.1 Market overview
15.1.2 Market size and forecast
16. Buying Criteria
17. Market Growth Drivers
18. Drivers and their Impact
19. Market Challenges
20. Impact of Drivers and Challenges
21. Market Trends
22. Trends and Their Impact
23. Vendor Landscape
23.1 Competitive scenario
23.1.1 Key news
23.1.2 Mergers and acquisitions
23.2 Market share analysis 2014
23.2.1 GlaxoSmithKline
23.2.2 AstraZeneca
23.2.3 F. Hoffmann-La Roche
23.2.4 Merck
23.3 Other and future prominent vendors
24. Key Vendor Analysis
24.1 AstraZeneca
24.1.1 Key facts
24.1.2 Business overview
24.1.3 Business segmentation by revenue 2013
24.1.4 Business segmentation by revenue 2011-2013
24.1.5 Sales by geography
24.1.6 Business strategy
24.1.7 Key developments
24.1.8 SWOT analysis
24.2 F. Hoffmann-La Roche
24.2.1 Key facts
24.2.2 Business overview
24.2.3 Business segmentation
24.2.4 Business segmentation by revenue 2012 and 2013
24.2.5 Sales by geography
24.2.6 Business strategy
24.2.7 Key information
24.2.8 SWOT analysis
24.3 GlaxoSmithKline
24.3.1 Key facts
24.3.2 Business overview
24.3.3 Business segmentation by revenue 2014
24.3.4 Business segmentation by revenue 2013 and 2014
24.3.5 Geographical segmentation by revenue 2014
24.3.6 Business strategy
24.3.7 Recent developments
24.3.8 SWOT analysis
24.4 Merck
24.4.1 Key facts
24.4.2 Business overview
24.4.3 Business segmentation by revenue 2013
24.4.4 Business segmentation by revenue 2012 and 2013
24.4.5 Sales by geography
24.4.6 Business strategy
24.4.7 Key developments
24.4.8 SWOT analysis
25. Other Reports in this Series
List of Exhibits
Exhibit 1: Market research methodology
Exhibit 2: Major diagnostic procedures for asthma
Exhibit 3: Asthma drugs market in US 2014-2019 ($ millions)
Exhibit 4: Segmentation of asthma drugs market in US by class of drug
Exhibit 5: Segmentation of asthma drugs market in US by class of drug 2014
Exhibit 6: Segmentation of asthma drugs market in US by class of drug 2019
Exhibit 7: Bronchodilators market in US 2014-2019 ($ millions)
Exhibit 8: Combination of LABAICS market in US 2014-2019 ($ millions)
Exhibit 9: Immunosuppressants market in US 2014-2019 ($ millions)
Exhibit 10: Leukotriene antagonists market in US 2014-2019 ($ millions)
Exhibit 11: Mast cell stabilizers market in US 2014-2019 ($ millions)
Exhibit 12: Major drivers of asthma drugs market in US
Exhibit 13: Major challenges in asthma drugs market in US
Exhibit 14: Major trends in asthma drugs market in US
Exhibit 15: Prescription chart of popular asthma drugs in US 2013
Exhibit 16: Market share analysis 2014
Exhibit 17: YoY growth rate of major asthma drugs 2011-2014 ($ millions)
Exhibit 18: GlaxoSmithKline: Global and US revenue of Breo Ellipta 2013 and 2014 ($ millions)
Exhibit 19: GlaxoSmithKline: Global revenue and YoY growth rate of Ventolin 2011-2014 ($ millions)
Exhibit 20: GlaxoSmithKline: US revenue and YoY growth rate of Ventolin 2011-2014 ($ millions)
Exhibit 21: GlaxoSmithKline: Global revenue and YoY growth rate of Flovent 2011-2014 ($ millions)
Exhibit 22: GlaxoSmithKline: US revenue and YoY growth rate of Flovent 2011-2014 ($ millions)
Exhibit 23: GlaxoSmithKline: Global revenue and YoY growth rate of Advair 2011-2014 ($ millions)
Exhibit 24: GlaxoSmithKline: US revenue and YoY growth rate of Advair 2011-2014 ($ millions)
Exhibit 25: GlaxoSmithKline: Global revenue and YoY growth rate of Serevent 2011-2014 ($ millions)
Exhibit 26: GlaxoSmithKline: US revenue and YoY growth rate of Serevent 2011-2014 ($ millions)
Exhibit 27: GlaxoSmithKline: US revenue of key asthma drugs 2011-2014 ($ millions)
Exhibit 28: AstraZeneca: Global revenue and YoY growth rate of Pulmicort 2011-2014 ($ millions)
Exhibit 29: AstraZeneca: US revenue and YoY growth rate of Pulmicort 2011-2014 ($ millions)
Exhibit 30: AstraZeneca: Global revenue and YoY growth rate of Symbicort 2011-2014 ($ millions)
Exhibit 31: AstraZeneca: US revenue and YoY growth rate of Symbicort 2011-2014 ($ millions)
Exhibit 32: AstraZeneca: US revenue of key asthma drugs 2011-2014 ($ millions)
Exhibit 33: F. Hoffmann-La Roche: Global revenue and YoY growth rate of Xolair 2011-2014 ($ millions)
Exhibit 34: Merck: Global revenue and YoY growth rate of Asmanex 2011-2013 ($ millions)
Exhibit 35: Merck: Global revenue and YoY growth rate of Dulera 2011-2014 ($ millions)
Exhibit 36: Merck: Global revenue and YoY growth rate of Singulair 2011-2014 ($ millions)
Exhibit 37: AstraZeneca: Business segmentation by revenue 2013
Exhibit 38: AstraZeneca: Business segmentation by revenue 2011-2013 ($ millions)
Exhibit 39: AstraZeneca: Sales by geography 2013
Exhibit 40: Business segmentation of F. Hoffmann-La Roche 2013
Exhibit 41: F. Hoffmann-La Roche: Business segmentation by revenue 2012 and 2013
Exhibit 42: F. Hoffmann-La Roche: Sales by geography 2013 (pharmaceuticals division)
Exhibit 43: F. Hoffmann-La Roche: Sales by geography 2013 (diagnostics division)
Exhibit 44: GlaxoSmithKline: Business segmentation by revenue 2014
Exhibit 45: GlaxoSmithKline: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 46: GlaxoSmithKline: Geographical segmentation by revenue 2014
Exhibit 47: Merck: Business segmentation by revenue 2013
Exhibit 48: Merck: Business segmentation by revenue 2012 and 2013 ($ billions)
Exhibit 49: Merck: Sales by geography 2013
